ChemicalBook > CAS DataBase List > Clopidogrel

Clopidogrel

Clopidogrel Structure
Clopidogrel
  • CAS No.113665-84-2
  • Chemical Name:Clopidogrel
  • CBNumber:CB3341209
  • Molecular Formula:C16H16ClNO2S
  • Formula Weight:321.82
  • MOL File:113665-84-2.mol
Clopidogrel Property
  • alpha D20 +51.52° (c = 1.61 in methanol)
  • Boiling point 423.7±45.0 °C(Predicted)
  • Density 1.317±0.06 g/cm3(Predicted)
  • storage temp. 2-8°C
  • solubility DMSO: 50mg/ml in DMSO
  • form Oil
  • pka 4.56±0.20(Predicted)
  • color Colorless to light yellow
  • InChI InChI=1/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/s3
  • InChIKey GKTWGGQPFAXNFI-UJHUVDBMNA-N
  • SMILES [C@@H](C1C=CC=CC=1Cl)(N1CCC2SC=CC=2C1)C(=O)OC |&1:0,r|
  • CAS DataBase Reference 113665-84-2(CAS DataBase Reference)
  • FDA UNII A74586SNO7
  • ATC code B01AC04
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H315-H319-H335
  • Precautionary statements P261-P305+P351+P338

Clopidogrel Chemical Properties,Usage,Production

  • Description Clopidogrel was launched in the US as a potent inhibitor of platelet aggregation for the preventive management of secondary ischemic events, including MI, stroke and vascular deaths. Clopidogrel can be synthesized in 4 steps (including an optical resolution to the S active enantiomer) from 2-(2- ch1orophenyl)-glycine, the key step being the cyclization to thienopyridine with formaldehyde and acetic acid. Clopidogrel belongs to the original chemical class of Ticlopidine, but shows fewer side effects (in particular, bone-marrowsuppressing effects) at the dosage generally used. Like Ticlopidine, it is an Adenosine diphosphate (ADP) antagonist acting at the purinergic P2y receptor. In in vivo experiments with rabbits, Clopidogrel shows a maximal antiaggregant effect at 20mg/kg po, reducing adhesion of platelets to the vascular subendothelium ; moreover, it reduces myointimal thickening occuring after endothelial injury of rat carotid artery. Clopigrel does not affect platelet aggregation in vitro ; actually, its in vivo activity is highly dependent on hepatic metabolism. The results of a CAPRIE trial (Clopidogrel versus Aspirin in patients at risk of ischemic events) demonstrated that Clopidogrel was well tolerated and more effective than aspirin.
  • Originator Sanofi (France)
  • Uses Sertraline metabolite
  • Uses anthelmintic, antiparasitic, antimite
  • Definition ChEBI: Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. It has a role as a platelet aggregation inhibitor, an anticoagulant and a P2Y12 receptor antagonist. It is a thienopyridine, a member of monochlorobenzenes and a methyl ester. It is functionally related to a ticlopidine.
  • brand name Plavix (Sanofi Aventis);Plavix, Iscover.
  • General Description Clopidogrel, methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (Plavix), is useful for the preventativemanagement of secondary ischemic events, including myocardialinfarction, stroke, and vascular deaths. It may beclassified as a thienopyridine because of its heterocyclicsystem. Several agents possessing this system have beenevaluated as potential antithrombotic agents. These agentshave a unique mechanism, in that they inhibit the purinergicreceptor located on platelets. Normally, nucleotides act asagonists on these receptors, which include the P2Y type.Two P2Y receptor subtypes (P2Y1 and P2Y2) found onplatelets, when stimulated by adenosine diphosphate (ADP),cause platelet aggregation.
  • Clinical Use Clopidogrel acts as an antagonistto the P2Y2 receptor. It is probably a prodrug that requiresmetabolic activation, because in vitro studies do not interferewith platelet aggregation. Although platelet aggregationis not normally seen in the first 8 to 11 days after administrationto a patient, the effect lasts for several days after thedrug therapy is discontinued. Unlike other thienopyridinescurrently used, clopidogrel does not seriously reduce thenumber of white cells in the blood, and therefore, routinemonitoring of the white blood cell count is not necessaryduring treatment.
  • Drug interactions Potentially hazardous interactions with other drugs
    Antibacterials: antiplatelet effect possibly reduced by erythromycin.
    Anticoagulants: enhanced anticoagulant effect with coumarins and phenindione; manufacturer advises to avoid with warfarin.
    Heparin: increased risk of bleeding.
    Antidepressants: antiplatelet effect possibly reduced by fluoxetine, fluvoxamine and moclobemide.
    Anti-diabetics: avoid with repaglinide if possible due to increased repaglinide exposure.
    Antiepileptics: antiplatelet effect possibly reduced by carbamazepine and oxcarbazepine.
    Antifungals: antiplatelet effect possibly reduced by fluconazole, itraconazole, ketoconazole and voriconazole.
    Antivirals: antiplatelet effect possibly reduced by etravirine.
    Statins: concentration of rosuvastatin increased, maximum rosuvastatin dose is 20 mg.
    Ulcer healing drugs: antiplatelet effect possibly reduced by cimetidine, lansoprazole, pantoprazole and rabeprazole; antiplatelet effect reduced by omeprazole and esomeprazole - avoid concomitant use if possible.
  • Metabolism Clopidogrel is a prodrug and is extensively metabolised in the liver, mainly to the inactive carboxylic acid derivative; metabolism is mediated by cytochrome P450 isoenzymes including CYP3A4 and CYP2B6, CYP1A2, CYP1A1, and CYP2C19. The active metabolite appears to be a thiol derivative
    Clopidogrel and its metabolites are excreted in urine and in faeces; about 50% of an oral dose is recovered from the urine and about 46% from the faeces.
Clopidogrel Preparation Products And Raw materials
Raw materials
Preparation Products
Clopidogrel Suppliers
Global(333)Suppliers
  • Supplier：
    airuikechemical co., ltd.
  • Tel：+86-18353166132<br/>+86-18353166132
  • Email：sales02@airuikechemical.com
  • Country：China
  • ProdList：983
  • Advantage：58
  • Supplier：
    Henan Tianfu Chemical Co.,Ltd.
  • Tel：+86-0371-55170693<br/>+86-19937530512
  • Email：info@tianfuchem.com
  • Country：China
  • ProdList：21629
  • Advantage：55
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：sales@coreychem.com
  • Country：China
  • ProdList：29860
  • Advantage：58
  • Supplier：
    Biochempartner
  • Tel：0086-13720134139
  • Email：candy@biochempartner.com
  • Country：CHINA
  • ProdList：965
  • Advantage：58
  • Supplier：
    Xiamen AmoyChem Co., Ltd
  • Tel：+86-86-5926051114<br/>+8615060885618
  • Email：sales@amoychem.com
  • Country：China
  • ProdList：6383
  • Advantage：58
  • Supplier：
    Chongqing Chemdad Co., Ltd
  • Tel：+86-023-6139-8061<br/>+86-86-13650506873
  • Email：sales@chemdad.com
  • Country：China
  • ProdList：39894
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58
Clopidogrel Spectrum
113665-84-2, ClopidogrelRelated Search:
  • Cardiovascular
  • API
  • API's
  • Pharmaceutical intermediates
  • REVOLUTION
  • 化学试剂
  • 抑制剂
  • 化工试剂
  • 医药体
  • 原料
  • 医药原料药
  • 细胞信号和神经生物学
  • 小分子抑制剂
  • G蛋白偶联受体&G蛋白
  • 原料药
  • 中间体
  • 药物
  • 血液系统用药
  • 医药与生物化工
  • 血液（造血系统）类药物
  • 医药中间体
  • 心血管类
  • C16H16ClNO2S
  • 65-84-2
  • 氯吡格雷及其中间体
  • PERFEMIKER]CLOPIDOGREL,98%
  • (S)-甲基 2-(2-氯苯基)-2-(6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-基)乙酸酯
  • 8-四氢-5-甲基-6-氧代-2-喋啶基]氨基]-3-甲氧基-N-(1-甲基-4-哌啶基)苯甲酰胺
  • 4-[[(7R)-8-环戊基-7-乙基-5
  • ()-(S)-氯吡格雷
  • (S)-(+)-2-(2-氯苯基)-2-(6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-基)乙酸甲酯
  • 氯吡格雷系统适用性 EP标准品
  • 氯吡格雷游离
  • S(+)-2-(2-氯苯基)-2-(4,5,6,7-四氢噻吩[3,2-C]并吡啶-5)乙酸甲酯
  • 氯吡格雷碱
  • 氯匹格雷
  • (S)-Α-(2-氯苯基)-6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-乙酸甲酯
  • 氯吡格雷硫氢酸盐
  • Α-(2-氯苯基)-2-(4,5,6,7-四氢噻吩3,2-C并吡啶-5(4H)乙酸甲酯硫酸氢盐
  • 氯吡格雷微丸50%
  • 氯吡格雷(外消旋)
  • 3 Α-(2-氯苯基)-2-(4,5,6,7-四氢噻吩[3,2-C]并吡啶-5(4H)乙酸甲酯硫酸氢盐
  • 氯匹多瑞(氯吡格雷游离碱)
  • D-(+)-甲基-A-( 4,5,6,7-四氢噻吩[3,2,C]吡啶(2-氯苯基)醋酸酯
  • 氯吡格雷杂质 C (SU)
  • 氯吡格雷-D4
  • (2S)-2-(2-氯苯基)-2-(4,5,6,7-四氢噻吩[3,2-c]并吡啶-5-基)乙酸甲酯
  • 克拉匹多
  • 氯匹多瑞
  • 氯吡格雷
  • 113665-84-2
  • Clopidogrel in methanol
  • Clopidogrel API
  • methyl (2s)-2-(2-chlorophenyl)-2-(9-thia-4-azabicyclo[4.3.0]nona-7,10-dien-4-yl)acetate
  • Clopidogrel 13CD3Q: What is Clopidogrel 13CD3 Q: What is the CAS Number of Clopidogrel 13CD3
  • Clopidogrel R-IsomerQ: What is Clopidogrel R-Isomer Q: What is the CAS Number of Clopidogrel R-Isomer
  • ClopidogrelQ: What is Clopidogrel Q: What is the CAS Number of Clopidogrel Q: What is the storage condition of Clopidogrel
  • methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate

Home

My